Production (Stage)
Gemina Laboratories Ltd.
GLAB
CNSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.85% | 108.75% | -26.70% | -26.73% | -28.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.93% | 27.70% | -6.26% | -43.27% | -53.88% |
| Operating Income | 16.26% | -27.70% | 6.26% | 43.27% | 53.88% |
| Income Before Tax | 11.99% | -77.21% | 26.42% | 40.59% | 51.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.99% | -77.21% | 26.42% | 40.59% | 51.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.99% | -77.21% | 26.42% | 40.59% | 51.80% |
| EBIT | 16.26% | -27.70% | 6.26% | 43.27% | 53.88% |
| EBITDA | 15.95% | -28.12% | 5.94% | 43.42% | 54.03% |
| EPS Basic | 15.66% | -78.67% | 27.35% | 40.37% | 54.14% |
| Normalized Basic EPS | 15.38% | -80.85% | 27.40% | 41.58% | 53.98% |
| EPS Diluted | 15.66% | -78.67% | 27.35% | 40.37% | 54.14% |
| Normalized Diluted EPS | 15.38% | -80.85% | 27.40% | 41.58% | 53.98% |
| Average Basic Shares Outstanding | 4.19% | -0.35% | 1.61% | 0.29% | 5.07% |
| Average Diluted Shares Outstanding | 4.19% | -0.35% | 1.61% | 0.29% | 5.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |